GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gossamer Bio Inc (NAS:GOSS) » Definitions » Equity-to-Asset

Gossamer Bio (Gossamer Bio) Equity-to-Asset : 0.10 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Gossamer Bio Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Gossamer Bio's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $26.72 Mil. Gossamer Bio's Total Assets for the quarter that ended in Mar. 2024 was $259.36 Mil.

The historical rank and industry rank for Gossamer Bio's Equity-to-Asset or its related term are showing as below:

GOSS' s Equity-to-Asset Range Over the Past 10 Years
Min: -15.42   Med: 0.35   Max: 0.94
Current: 0.1

During the past 8 years, the highest Equity to Asset Ratio of Gossamer Bio was 0.94. The lowest was -15.42. And the median was 0.35.

GOSS's Equity-to-Asset is ranked worse than
82.26% of 1567 companies
in the Biotechnology industry
Industry Median: 0.66 vs GOSS: 0.10

Gossamer Bio Equity-to-Asset Historical Data

The historical data trend for Gossamer Bio's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gossamer Bio Equity-to-Asset Chart

Gossamer Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial 0.83 0.59 0.35 0.04 0.20

Gossamer Bio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.13 -0.35 0.30 0.20 0.10

Competitive Comparison of Gossamer Bio's Equity-to-Asset

For the Biotechnology subindustry, Gossamer Bio's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gossamer Bio's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gossamer Bio's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Gossamer Bio's Equity-to-Asset falls into.



Gossamer Bio Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Gossamer Bio's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=62.769/311.916
=

Gossamer Bio's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=26.722/259.36
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gossamer Bio  (NAS:GOSS) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Gossamer Bio Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Gossamer Bio's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Gossamer Bio (Gossamer Bio) Business Description

Traded in Other Exchanges
Address
3013 Science Park Road, Suite 200, San Diego, CA, USA, 92121
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Executives
Sandra Milligan director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Bryan Giraudo officer: Chief Financial Officer 7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560
Richard Aranda officer: Chief Medical Officer 3013 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Faheem Hasnain director, officer: Executive Chairman 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Waage Christian officer: EVP & General Counsel RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Caryn Peterson officer: EVP, Regulatory Affairs 3013 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Laura Carter officer: Chief Scientific Officer 3013 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Luisa Salter-cid officer: Chief Scientific Officer C/O GOSSAMER BIO, INC., 3013 SCIENCE PARK ROAD, SUITE 200, SAN DIEGO CA 92121
Jakob Dupont officer: Chief Medical Officer C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Sheila Gujrathi director, officer: President & CEO 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Omega Fund V Gp, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V Gp Manager, Ltd. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Otello Stampacchia director, 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Russell J. Cox director C/O JAZZ PHARMACEUTICALS, PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2